References
- Overgaard K., Sereghy T., Boysen G., Pedersen H., Høyer S., Diemer N. H. A rat model of reproducible cerebral infarction using thrombotic blood clot emboli. J Cereb Blood Flow Metab 1992; 12: 484–90
- Zivin J. A., Fisher M., Degirolami U., Hemenway C. C., Stashak J. A. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985; 230: 1289–92
- Zivin J. A., Lyden P. D., Degirolami U., Kochhar A., Mazzarella V., Hemenway C. C., Johnston P. Reduction of neurologic damage after experimental embolic stroke. Arch neurol 1988; 45: 387–91
- Phillips D. A., Fisher M., Davis M. A., Smith T. W., Pang R. HL. Delayed treatment with a t-PA analogue and streptokinase in a rabbit embolic stroke model. Stroke 1990; 21: 602–5
- Penar P. L., Greer C. A. The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia. Yale. J Biol Med 1987; 60: 233–43
- Benes V., Zabramski J. M., Boston M., Puca A., Spetzler R. F. Effect of intra-arterial antifibrinolytic agents on autologous arterial emboli in the cerebral circulation of rabbits. Stroke 1990; 21: 1594–99
- Bednar M. M., McAuliffe T., Raymond S., Gross C. E. Tissue plasminogen activator reduced brain injury in a rabbit model of thromboembolic stroke. Stroke 1990; 21: 1705–9
- Chehrazi B. B., Seibert J. A., Kissel P., Hein L., Brock J. M. Evaluation of recombinant tissue plasminogen activator in embolic stroke. Neurosurgery 1989; 24: 355–60
- Overgaard K., Sereghy T., Boysen G., Pedersen H., Diemer N. H. Reduction of infarct volume and mortality by thrombolysis with rt-PA in an embolic stroke model. Stroke 1992; 23: 1167–74
- Bederson J. A., Pitts L. H., Germano S. M., Nishimura M. C., Davis R. L., Bartkowski H. M. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986; 17: 1304–8
- Bederson J. B., Pitts L. H., Tsun M., Nishimura M. C., Davis R. L., Bartkowski H. Rat middle cerebral artery occlusion: Evaluation of the model and development of a neurologic examination. Stroke 1986; 17: 472–6
- Kaneko D., Nakamura N., Ogawa T. Cerebral infarction in rats using homologous blood emboli: Development of a new experimental model. Stroke 1985; 16: 76–84
- Papadopoulos S. M., Chandler W. F., Salamat M. S., Topol E. J., Sackellares J. C. Recombinant tissue-type plasminogen activator therapy in acute thrombo-embolic stroke. J Neurosurg 1987; 67: 394–8
- Korninger C., Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 1981; 46: 561–5
- Cole D. J., Drummond J. C., Ghazal E. A., Shapiro H. M. A reversible component of cerebral injury as identified by the histochemcial stain 2,3,5-triphenyltetrazolium chloride (TTC). Acta. Neuropathol. 1990; 80: 152–5
- Zivin J. A., Choi D. W. Stroke therapy. Sci American 1991; 265: 36–43
- Kudo M., Aoyama A., Ischimori S., Fukunaga N. An animal model of cerebral infarction. Homologous blood clot emboli in rats. Stroke 1982; 13: 505–8